A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

被引：0
|
作者：
Tillmanns, T. D.
Lowe, M. P.
Schwartzberg, L. S.
Walker, M. S.
Stepanski, E. J.
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] West Clin, Memphis, TN USA
[3] ACORN Res, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5009
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
    Tillmanns, Todd D.
    Lowe, M. Patrick
    Walker, Mark S.
    Stepanski, Edward J.
    Schwartzberg, Lee S.
    GYNECOLOGIC ONCOLOGY, 2013, 128 (02) : 221 - 228
  • [2] A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study
    Coleman, R. L.
    Brady, W.
    McMeekin, D. S.
    Rose, P. G.
    Soper, J. T.
    Lentz, S. S.
    Hoffman, J. S.
    Shahin, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer
    Benigno, B. B.
    Burrell, M. O.
    Daugherty, P.
    Hernandez, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Nagao, Shoji
    Kogiku, Ai
    Suzuki, Kazuhiro
    Shibutani, Takashi
    Yamamoto, Kasumi
    Jimi, Tomoatsu
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Yamaguchi, Satoshi
    JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [5] A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Shoji Nagao
    Ai Kogiku
    Kazuhiro Suzuki
    Takashi Shibutani
    Kasumi Yamamoto
    Tomoatsu Jimi
    Miho Kitai
    Takaya Shiozaki
    Kazuko Matsuoka
    Satoshi Yamaguchi
    Journal of Ovarian Research, 13
  • [6] EFFICACY AND SAFETY OF ANLOTINIB PLUS ALBUMIN-BOUND PACLITAXEL IN PATIENTS WITH RECURRENT, PLATINUM-RESISTANT PRIMARY EPITHELIAL OVARIAN OR PERITONEAL CARCINOMA: A PROSPECTIVE PHASE II CLINICAL TRIAL
    Li Yanfang
    Zhou, Yun
    Zhou, Jian
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A176 - A177
  • [7] Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study
    Ghamande, SA
    Piver, MS
    JOURNAL OF SURGICAL ONCOLOGY, 1999, 72 (03) : 162 - 166
  • [8] A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, R. E.
    Childs, J.
    Higgins, D.
    Gooley, T.
    Goff, B. A.
    Fintak, P. A.
    Buening, B.
    Disis, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Paclitaxel in platinum-resistant epithelial ovarian carcinoma
    Wardley, AM
    Jenkins, A
    Alison, DL
    Perren, TJ
    BRITISH JOURNAL OF CANCER, 2000, 83 : 79 - 79
  • [10] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Cannistra, Stephen A.
    Matulonis, Ursula A.
    Penson, Richard T.
    Hambleton, Julie
    Dupont, Jakob
    Mackey, Howard
    Douglas, Jeffrey
    Burger, Robert A.
    Armstrong, Deborah
    Wenham, Robert
    McGuire, William
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
12345